Blocking the mTOR pathway: A drug discovery perspective

Biochemical Society Transactions

Volumn 39, Issue 2, 2011, Pages 451-455

  Garcia Echeverria, Carlos ^a  

^a SANOFI   (France)

Author keywords

Cancer; Mammalian target of rapamycin inhibitor (mTOR inhibitor); Phosphoinositide 3 kinase (PI3K); Rapalogue; Targeted therapy

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; AZD 2014; AZD 8055; AZD D2014; EVEROLIMUS; FK 506 BINDING PROTEIN; GDC 0980; GSK 2126458; GSK 2141795; INITIATION FACTOR 4E; INITIATION FACTOR 4E BINDING PROTEIN; INK 128; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MK 2206; OSI 027; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B INHIBITOR; RAPAMYCIN; RAPAMYCIN DERIVATIVE; RIDAFOROLIMUS; SAR 245409; SELUMETINIB; TEMSIROLIMUS; UNCLASSIFIED DRUG; XL 765;

ALLOSTERISM; ANGIOMYOLIPOMA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CELL; CANCER PATIENT; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; DRUG MECHANISM; DRUG SELECTIVITY; DRUG TARGETING; EXPERIMENTAL NEOPLASM; HUMAN; KIDNEY CARCINOMA; MANTLE CELL LYMPHOMA; NEGATIVE FEEDBACK; NONHUMAN; PHARMACODYNAMICS; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; REVIEW; TUBEROUS SCLEROSIS; TUMOR MODEL;

ALLOSTERIC REGULATION; ANIMALS; BINDING, COMPETITIVE; DRUG DISCOVERY; HUMANS; MOLECULAR TARGETED THERAPY; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES;

MAMMALIA;

EID: 79953204005     PISSN: 03005127     EISSN: 14708752     Source Type: Journal    
DOI: 10.1042/BST0390451     Document Type: Review

References (40)

1. Garcia-Echeverria, C. and Sellers, W.R. (2008) Drug discovery approaches targeting the PI3K/Akt pathway in cancer. Oncogene 27, 5511-5526
2. Garcia-Echeverria, C. (2010) Allosteric and ATP-competitive kinase inhibitors of mTOR. Bioorg. Med. Chem. Lett. 20, 4308-4312
3. Yang, Q. and Guan, L. (2007) Expanding mTOR signaling. Cell Res. 17, 666-681 (Pubitemid 47255937)
4. Guertin, D.A. and Sabatini, D.M. (2007) Defining the role of mTOR in cancer. Cancer Cell 12, 22
5. Engelman, J.A. (2009) Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat. Rev. 9, 550-562
6. Maira, S.M., Furet, P. and Stauffer, F. (2009) Discovery of novel anticancer therapeutics targeting the PI3K/Akt/mTOR pathway. Future Med. Chem. 1, 137-155
7. Choi, J., Chen, J., Schreiber, S.L. and Clardy, J. (1996) Structure of the FKBP12-rapamycin complex interacting with binding domain of human FRAP. Science 273, 239-242 (Pubitemid 26285890)
8. Yonezawa, K., Tokunaga, C., Oshiro, N. and Yoshino, K. (2004) Raptor, a binding partner of target of rapamycin. Biochem. Biophys. Res. Commun. 313, 437-441
9. Sarbassov, D.D., Ali, S.M., Sengupta, S., Sheen, J.H., Hsu, P.P., Bagley, A.F., Markhord, A.L. and Sabatini, D.M. (2006) Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol. Cell 22, 159-168
10. Masri, J., Bernath, A., Martin, J., Jo, O.D., Vartanian, R., Funk, A. and Gera, J. (2007) mTORC2 activity is elevated in gliomas and promotes growth and cell motility via overexpression of rictor. Cancer Res. 67, 11712-11720
11. Hietakangas, V. and Cohen, S.M. (2008) TOR complex 2 is needed for cell cycle progression and anchorage-independent growth of MCF7 and PC3 tumor cells. BMC Cancer 8, 282
12. Guertin, D.A., Stevens, D.M., Saitoh, M., Kinkel, S., Crosby, K., Sheen, J.H., Mulholland, D.J., Magnuson, M.A., Wu, H. and Sabatini, D.M. (2009) mTOR complex 2 is required for the development of prostate cancer induced by PTEN loss in mice. Cancer Cell 15, 148-159
13. Strimpakos, A.S., Karapanagiotou, E.M., Saif, W.M. and Syrigos, K.N. (2008) The role of mTOR in the management of solid tumors. Cancer Treat. Rev. 35, 148-159
14. Tabernero, J., Rojo, F., Calvo, E., Burris, H., Judson, I., Hazell, K., Martinelli, E., Ramon y Cajal, S., Jones, S., Vidal, L. et al. (2008) Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor phamacodynamic study in patients with advanced solid tumors. J. Clin. Oncol. 26, 1603-1609
15. Motzer, R.J., Escudier, B., Oudard, S., Hutson, T.E., Porta, C., Bracarda, S., Grünwald, V., Thompson, J.A., Figlin, R.A., Hollaender, N. et al. (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase II trial. Lancet 372, 449-456
16. Hudes, G., Carducci, M., Tomczak, P., Dutcher, J., Figlin, R., Kapoor, A., Staroslawaska, E., Sosman, J., McDermott, D., Bodrogi, I. et al. (2007) Temsirolimus, interferon ?, or both for advanced renal-cell carcinoma. N. Engl. J. Med. 356, 2271-2281
17. Kaelin, Jr, W.G. (2007) Von Hippel-Lindau disease. Annu. Rev. Pathol. 2, 145-173
18. Kenerson, H., Folpe, A.L., Takayama, T.K. and Yeung, R.S. (2007) Activation of the mTOR pathway in sporadic angiomyolipomas and other perivascular epithelioid cell neoplasms. Human Pathol. 38, 1361-1371 (Pubitemid 47247479)
19. O'Reilly, K.E., Rojo, F., She, Q.B., Solit, D., Mills, G.B., Smith, D., Lane, H., Hofmann, F., Hicklin, D.J., Ludwig, D.L. et al. (2006) mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 66, 1500-1508 (Pubitemid 43259931)
20. Carracedo, A., Ma, L., Teruya-Feldstein, J., Rojo, F., Salmera, L., Alimonti, A., Egia, A., Sasaki, A.T., Thomas, G., Kozma, S.C. et al. (2008) Inhibition of mTORC1 leads to MAPK pathway activation trough a PI3K-dependent feedback loop in human cancer. J. Clin. Invest. 118, 3065-3074
21. Meric-Bernstam, F. and Gonzalez-Angulo, A.M. (2009) Targeting the mTOR signaling network for cancer therapy. J. Clin. Oncol. 27, 2278-2287
22. Maira, S.-M., Stauffer, F., Brueggen, J., Furet, P., Schnell, C., Fritsch, C., Brachmann, S., Chène, P., De Pover, A., Shoemaker, K. et al. (2008) Identification and characterization of NVP-BEZ235, a new orally available dual PI3K/mTor inhibitor with potent in vivo antitumor activity. Mol. Cancer Ther. 7, 1851-1863
23. Knight, S.D., Adams, N.D., Burgess, J.L., Chaudhari, A.M., Darcy, M.G., Donatelli, C.A., Luengo, J.I., Newlander, K.A., Parrish, C.A., Ridgers, L.H. et al. (2010) Discovery of GSK2126458, a highly potent inhibitor of PI3K and the mammalian target of rapamycin. ACS Med. Chem. Lett. 1, 39-43
24. Stauffer, F., Maira, S.-M., Furet, P. and Garcia-Echeverria, C. (2008) Imidazo[45-c]quinolines as inhibitors of the PI3K/PKB-pathway. Bioorg. Med. Chem. Lett. 18, 1027-1030
25. Brachmann, S.M., Hofmann, I., Schnell, C., Fritsch, C., Wee, S., Lane, H., Wang, S., Garcia-Echeverria, C. and Maira, S.M. (2009) Specific apoptosis induction by the dual PI3K/mTOR inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells. Proc. Natl. Acad. Sci. U.S.A. 106, 22299-22304
26. Engelman, J.A., Chen, L., Tan, X., Crosby, K., Guimares, A.R., Upadhyay, R., McNamara, K., Perera, S.A., Song, Y., Chirieac, L.R. et al. (2008) Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat. Med. 14, 1315-1316
27. Faber, A.C., Li, D., Sing, Y., Liang, M.C., Yeep, B.Y., Bronson, R.T., Lifshits, E., Chen, Z., Maira, S.M., Garcia-Echeverria, C. et al. (2009) Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition. Proc. Natl. Acad. Sci. U.S.A. 106, 19503-19508
28. Yuan, T.L., Choi, H.S., Matsui, A., Benes, C., Lifshits, E., Luo, J., Frangioni, J.V. and Cantley, L.C. (2008) Class 1A PI3K regulates vessel integrity during development and tumorigenesis. Proc. Natl. Acad. Sci. U.S.A. 105, 9739-9744
29. Schnell, C., Stauffer, F., Allegrini, P.R., O'Reilly, T., McSheehy, P.M.J., Dartois, C., Stumm, M., Cozens, R., Littlewood-Evans, A., Garcia-Echeverria, C. and Maira, S.-M. (2008) Effects of the dual PI3K/mTOR inhibitor NVP-BEZ235 on the tumor vasculature: implications for clinical imaging. Cancer Res. 68, 6598-65507
30. Courtney, K.D., Corcoran, R.B. and Engelman, J.A. (2010) The PI3K pathway as drug target in human cancer. J. Clin. Oncol. 28, 1075-1083
31. Brana, I., LoRusso, P., Baselga, J., Heath, E., Patnaik, A., Gendreau, S., Laird, A. and Papadopoulos, K. (2010) A Phase I dose-escalation study of the safety, pharmacokinetics and pharmacodynamics of XL765 (SAR245409), a PI3K/TORC1/TORC2 inhibitor administered orally to patients with advanced malignancies. 2010 ASCO Annual Meeting, Chicago, IL, U.S.A., 4-8 June 2010, Abstract 3030
32. Zunder, E.R., Knight, Z.A., Houseman, B.T., Apsel, B. and Shokat, K.M. (2008) Discovery of drug-resistant and drug-sensitizing mutations in the oncogenic PI3K isoform p110?. Cancer Cell 14, 107-108
33. Thoreen, C.C., Kang, S.A., Chang, J.W., Liu, Q., Zhang, J., Gao, Y., Reichling, L.J., Sim, T., Sabatini, D.M. and Gray, N.S. (2009) An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J. Biol. Chem. 284, 8023-8032
34. Apsel, B., Blair, J.A., Gonzalez, B., Nazif, T.M., Feldman, M.E., Aizenstein, B., Hoffman, R., Williams, R.L., Shokat, K.M. and Knight, Z.A. (2008) Target polypharmacology/discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat. Chem. Biol. 4, 691-699
35. Feldman, M.E., Apsel, B., Uotila, A., Loewith, R., Knight, Z.A., Ruggero, D. and Shokat, K.M. (2009) Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol. 7, 371-383
36. Yu, K., Shi, C., Toral-Barza, L., Lucas, J., Shor, B., Kim, J.E., Zhang, W.-G., Mahoney, R., Gaydos, C., Tardio, L. et al. (2010) Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-12512, an ATP-competitive and specific inhibitor of mTORC1 and MTORC2. Cancer Res. 70, 621-631
37. Liu, Q., Chang, J.W., Wang, J., Kang, S.A., Thoreen, C.C., Markhard, A., Hur, W., Zhang, J., Sim, T., Sabatini, D.M. and Gray, N.S. (2010) Discovery of 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl) benzo[h][16]naphrhyridin-2(1H)-one as a highly potent, selective mammalian target of rapamycin (mTOR) inhibitor for the treatment of cancer. J. Med. Chem. 53, 7146-7155
38. Hsieh, A.C., Costa, M., Zollo, O., Feldman, M.E., Testa, J.R., Meyuhas, O., Shokat, K.M. and Ruggero, D. (2010) Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E. Cancer Cell 17, 249-261
39. Chresta, C.M., Davies, B.R., Hickson, I., Harding, T., Cosulich, S., Critchlow, S.E., Vincent, J.P., Ellston, R., Jones, D., Sini, P. et al. (2010) AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res. 70, 288-298
40. Carracedo, A. and Pandolfi, P.P. (2008) The PTEN-PI3K pathway: of feedbacks and cross-talks. Oncogene 27, 5527-5541